{"id":"NCT03210259","sponsor":"Boehringer Ingelheim","briefTitle":"The VOLTAIRE-X Trial Looks at the Effect of Switching Between Humira® and BI 695501 in Patients With Plaque Psoriasis","officialTitle":"VOLTAIRE-X: Pharmacokinetics, Safety, Immunogenicity and Efficacy of BI 695501 Versus Humira® in Patients With Moderate to Severe Chronic Plaque Psoriasis: a Randomized, Double-blind, Parallel-arm, Multiple-dose, Active Comparator Trial","status":"COMPLETED","phase":"PHASE3","dates":{"start":"2017-07-10","primaryCompletion":"2019-04-16","completion":"2019-04-16","firstPosted":"2017-07-06","resultsPosted":"2021-07-02","lastUpdate":"2021-07-14"},"enrollment":259,"design":{"allocation":"RANDOMIZED","model":"PARALLEL","masking":"DOUBLE","primaryPurpose":"TREATMENT"},"conditions":["Psoriasis"],"interventions":[{"type":"DRUG","name":"Humira®","otherNames":[]},{"type":"DRUG","name":"BI 695501","otherNames":["CYLTEZO"]}],"arms":[{"label":"BI 695501","type":"EXPERIMENTAL"},{"label":"Humira®","type":"ACTIVE_COMPARATOR"}],"summary":"The primary objective of the trial is to assess the PK similarity between patients receiving Humira® continuously vs those who alternate between BI 695501 and Humira®, in patients with moderate-to-severe chronic plaque psoriasis.\n\nThe secondary objectives of this trial are to descriptively compare the safety, immunogenicity and efficacy profiles between patients receiving Humira® continuously vs those who alternate between BI 695501 and Humira®.","primaryOutcome":{"measure":"Area Under the Plasma Concentration Time Curve Over the Dosing Interval of Week 30 to 32 (AUCτ, 30-32) for Adalimumab in Plasma","timeFrame":"Pre-dose at Week 30, at 72, 120, 168 and 240 hours after the Week 30 dosing, and pre-dose at Week 32.","effectByArm":[{"arm":"Switching Arm (Post-Randomization Period)","deltaMin":2040,"sd":1420},{"arm":"Continuous Humira (Post-Randomization Period)","deltaMin":1980,"sd":1600}],"pValues":[{"comp":"OG000 vs OG001","p":null}]},"eligibility":{"minAge":"18 Years","sex":"ALL","healthyVolunteers":false,"inclusionCount":4,"exclusionCount":23},"locations":{"siteCount":49,"countries":["United States","Germany","Hungary","Latvia","Poland","Russia","Ukraine"]},"refs":{"pmids":["35934770"],"seeAlso":[]},"adverseEventsSummary":{"seriousAny":{"events":6,"n":259},"commonTop":["Nasopharyngitis","Headache"]}}